Our current study reveals a critical role for the chemotherapy‐enriched CD133 expressing cells that preferentially secrete less ECM‐modifying enzyme THBS2 to promote aggressive cancer and stemness properties in HCC. The gene discussed is PROM1; the disease is cancer.